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Abstract
Xenoestrogens are either natural or synthetic compounds that mimic the effects of endogenous estrogen. These
compounds, such as bisphenol-A (BPA), and phthalates, are commonly found in plastic wares. Exposure to these
compounds poses major risk to human health because of the potential to cause endocrine disruption. There is huge
demand for a wide range of chemicals to be assessed for such potential for the sake of public health. Classical in
vivo assays for endocrine disruption are comprehensive but time-consuming and require sacrifice of experimental
animals. Simple preliminary in vitro screening assays can reduce the time and expense involved. We previously
demonstrated that catechol-O-methyltransferase (COMT) is transcriptionally regulated by estrogen via estrogen
receptor (ER). Therefore, detecting corresponding changes of COMT expression in estrogen-responsive cells may be
a useful method to estimate estrogenic effects of various compounds. We developed a novel cell-based ELISA to
evaluate cellular response to estrogenicity by reduction of soluble-COMT expression in ER-positive MCF-7 cells
exposed to estrogenic compounds. In contrast to various existing methods that only detect bioactivity, this method
elucidates direct physiological effect in a living cell in response to a compound. We validated our assay using three
well-characterized estrogenic plasticizers - BPA, benzyl butyl phthalate (BBP), and di-n-butyl phthalate (DBP). Cells
were exposed to either these plasticizers or 17β-estradiol (E2) in estrogen-depleted medium with or without an ER-
antagonist, ICI 182,780, and COMT expression assayed. Exposure to each of these plasticizers (10-9-10-7M) dose-
dependently reduced COMT expression (p<0.05), which was blocked by ICI 182,780. Reduction of COMT
expression was readily detectable in cells exposed to picomolar level of E2, comparable to other in vitro assays of
similar sensitivity. To satisfy the demand for in vitro assays targeting different cellular components, a cell-based
COMT assay provides useful initial screening to supplement the current assessments of xenoestrogens for potential
estrogenic activity.
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Introduction
Estrogens regulate endocrine, developmental and
reproductive systems in human. Many chemicals or
substances, both synthetic and naturally occurring, mimic or
inhibit the actions of estrogen (generally classified as
xenoestrogens). If introduced in humans, such chemicals
disrupt the normal actions of estradiol and cause a wide
spectrum of endocrine disruptive problems at all stages of life,
including early puberty, disturbance of spermatogenesis and
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hormone synthesis, and prostatic and breast cancers [1,2].
Catechol-O-methyltransferase (COMT) is an enzyme
ubiquitously expressed in various human tissues to degrade
catecholamines and thus facilitate the removal of hormones
(e.g. estrogen) from the body. The carcinogenic intermediate
catechol estrogens (e.g., 4-hydroxyestradiol) generated from
hydroxylation of endogenous estrogens and xenoestrogens by
CYP450 are inactivated by COMT, or they are further oxidized
into reactive quinones causing oxidative stress [3].
Endogenous COMT activity is a major determinant in
facilitating estrogen metabolism, and it plays an important role
in the pathophysiology of different human disorders including
Parkinson’s disease, depression, schizophrenia, hypertension,
and various estrogen-induced cancers [3–9].
To address the health concerns of the endocrine disruptors,
large number of chemicals are required to be tested for
estrogenic endocrine disrupting properties. The classical
method of carrying out such an assessment is the in vivo “two-
generation” rat test [10]. However, this requires a considerable
number of animals, which runs counter to the reduction in the
number of animals used in animal testing protocols.
Subsequently, several means of speeding up the testing
process and reducing the number of mammals required have
been devised. These include the in vivo luciferase-dependent
gene promoter activity tests in zebrafish [11], and a series of in
vitro screening assays which focus on three different aspects:
the estrogenic-stimulation to cell proliferation assay (E-
SCREEN), the estrogen receptor binding assay, and the
estrogen-receptor (ER) transcriptional activation via reporter
gene in yeast or mammalian cells [12,13]. These assays have
advantages and limitations [14,15]. Nevertheless, there is no
single assay that can satisfactorily predict such a diverse
spectrum of estrogenic effects, nor was it be able to determine
the adverse physiological responses induced by the testing
agents.
Previously we have shown that endogenous COMT
expression is not only transcriptionally regulated by estrogen
via the estrogen-response-element (ERE) in its gene promoter
region [8,16] but also by compounds of widely different
chemical structures but which have the capacity to either mimic
or antagonize the actions of estradiol [17,18]. In particular,
xenoestrogens such as polychlorinated biphenyls (PCBs) and
phthalate-based plasticizers (e.g. bis-isohexyl phthalate,
octylphenol), which are commonly used in the manufacture of
plastic products, have long been classified as potent estrogenic
endocrine disruptors. Thus assaying changes of COMT
expression in response to these estrogenic agents may be one
of the useful methods to estimate estrogenicity. In this
communication, we describe a cell-based system to assess
estrogenic agents, which utilizes a novel competitive ELISA,
based on exclusive expression of soluble-form catechol-O-
methyltransferase (S-COMT) isoform in a ER-positive human
breast adenocarcinoma MCF-7 cell line [19]. To evaluate the
assessment of estrogenic effects by COMT assay, we have
tested three common plasticizers - bisphenol-A (BPA), benzyl
butyl phthalate (BBP) and di-n-butyl phthalate (DBP), with
known disruptive properties to estrogenic action [20]. The
results from this novel assay were compared with those
obtained using classical SDS-PAGE/Western blotting.
Results
BPA, BBP and DBP dose-dependently decreased COMT
protein expression in Western blotting
When MCF-7 cells were cultured with graded doses of either
BPA (10-5, 10-7, and 10-9M), or BBP (10-7 and 10-9M), or DBP
(10-7 and 10-9M), for 48 hours in charcoal-stripped medium,
there was a concentration dependent decrease in S-COMT
levels for all three tested compounds relative to controls (BPA:
10-5M: p<0.01; 10-7M: p<0.05, n=4; BBP: 10-7M: p<0.01, 10-9M:
p<0.05 n=3; DBP: 10-7M: p<0.01; n=3) (Figure 1). However,
when these cells were treated together with the ER-antagonist,
ICI 182,780, such concentration dependent decrease of COMT
expression was abolished (p<0.05), as compared with the
corresponding group without ICI 182,780 (Figure 1). The final
concentration of solvent DMSO in culture medium was 0.05%
(v/v), which did not affect COMT protein expression level (data
not shown).
Development of competitive COMT ELISA - Structure of
human recombinant MB-COMT-NE standard protein
and validation of NE antibody specificity
The protein structure of the recombinant MB-COMT and its
purity after extraction from E. Coli is shown in SDS-PAGE after
Coomassie blue staining of the gel (Figure 2A). These proteins
extracted from E. Coli were used as standard proteins in the
Figure 1.  Three common plasticizers (bisphenol-A (BPA),
benzyl butyl phthalate (BBP), and di-n-butyl phthalate
(DBP)) dose-dependently decreased COMT expression via
estrogen receptor (ER) in MCF-7 cells.  Cells were treated
with graded doses of each of the three compounds, in the
absence or presence of ICI 182,780 (ER antagonist). The
resultant changes of soluble-COMT (S-COMT; 23kDa) protein
expression were determined by Western blotting. Equal loading
of samples were normalized by actin (42kDa). Results are
mean ± SEM of four separate experiments (n=4). Statistical
significance at the level of *p<0.05 or **p<0.01, as compared to
untreated controls. ## p<0.01, as compared between the two
designated treatment groups.
doi: 10.1371/journal.pone.0074065.g001
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ELISA. On the other hand, the specificity of NE antibody was
validated by immunoprecipitation and SDS-PAGE/Western blot
in HEK293 cell lysate overexpressing MB-COMT-NE (Figure
2B). Recombinant MB-COMT-NE protein in total cell lysate
extracted from HEK293 cells was immunoadsorbed by either
anti-COMT or anti-NE antibodies, and cross-detected on SDS-
PAGE/Western blots. On the Western blots of lysate which has
undergone immuno-precipitated with anti-COMT and probed
with either anti-COMT or anti-NE antibodies, there was no
antibody binding at a position appropriate for MB-COMT in
vector control cell lysate (i.e. without expression of MB-COMT-
NE (Figure 2B, lane 1 and 3). In contrast, single band was
observed corresponding to MB-COMT-NE (32kDa) in anti-
COMT pull-down lysate from cells overexpressing MB-COMT-
NE in blots probed with either anti-COMT or anti-NE (Figure
2B, lanes 2 and 4). Similar results were seen when cell lysates
were immuno-precipitated with anti-NE and the resultant
precipitated subjected to SDS-PAGE/Western blotting (Figure
2B, lanes 5 to 8).
Characterization of COMT ELISA
The competitive ELISA gave responses which were inversely
correlated to standard recombinant MB-COMT concentration
and when fitted by a nonlinear curve-fitting algorithm gave
sigmoid curves with r2 values ranging between 0.97 and 1.0,
determined as a plot of log agonist concentration against
response in six independent trials; the mean curve ± S.E.M.
with mean EC50 (26.34µg/ml; 95% confidence intervals = 20.26
to 34.2µg/ml) is shown in Figure 3A. The above six curves
were plotted with a further seven curves (response at x mg MB-
COMT concentration divided by response at zero MB-COMT
concentration against log MB-COMT concentration) to illustrate
the consistency of the method (Figure 3B), with ±4% standard
error for inter-variation. Intra-variation between eight wells
assayed for the same sample was ±1.5%. These gave
Figure 2.  Bacterial expression, purification, and
characterization of recombinant MB-COMT protein
standard.  (A) Structure of the engineered gene to yield full-
length human recombinant membrane-bound-COMT (MB-
COMT) protein, and the purity of the recombinant protein by
SDS-PAGE following extraction from E. Coli. NE is a novel 18-
amino-acid protein tag attached to MB-COMT for detection in
the competitive COMT ELISA. (B) Results of SDS-PAGE/
Western blotting probed with anti-COMT (lanes 1-4) or anti-NE
(lanes 5-8) following immunoprecipitation by either anti-COMT
(lanes 1, 2 & 5, 6) or anti-NE (lanes 3, 4 & 7, 8).
doi: 10.1371/journal.pone.0074065.g002
curvilinear plots with r-values ranging between 0.97 and 1.0.
The average sensitivity (minimum concentration of MB-COMT
practically detectable) of the ELISA was 0.8ng/µl.
It was important to determine whether the recombinant
protein used as standards in the ELISA and human soluble-
COMT (S-COMT) in MCF-7 cell lysate behaved in the same
way in the ELISA. To demonstrate this, MCF-7 lysate was
serially diluted with BSA solution to maintain an equal total
protein concentration in all samples. Aliquots of these replaced
the recombinant standards within the ELISA. The diluted
lysates gave a linear response in the ELISA a similar manner
to the recombinant standards (Figure 3C). The concentration of
COMT in lysates of normal untreated MCF-7 cells was at a
level of 36.4µg/mg total protein, being comparable with results
in previous literature [21] (i.e. 8.1 ± 1.5 µg/mg).
COMT assay by competitive ELISA – Effect of 17β-
estradiol
Treatment with 17β-estradiol (10-12-10-6M) for 48 hours
caused a reduction in COMT expression compared with the
results for untreated control cells (10-12-10-6M, all p<0.01, n=6;
Figure 3D) in a dose-dependent manner (Spearman r = 0.81;
Figure 3.  Characterization and application of COMT
ELISA.  (A) EC50 determination from mean competitive curve ±
S.E.M. (B) Combination plots of 13 individual standard curves
illustrating the consistency of the method. (C) Calibration curve
used in the ELISA generated from a serial dilution of untreated
MCF-7 lysate (COMT concentration: 36.4µg/mg total protein).
The lysate gave a linear response under the conditions of the
ELISA in a highly similar fashion to that of the purified
recombinant MB-COMT standards. (D) Effects of graded doses
of 17β-estradiol (E2) on COMT expression in MCF-7 cells
determined by COMT ELISA after 48-hour treatment. (E)
Effects of treatment of MCF-7 cells with graded doses of BPA,
BBP, and DBP, in the presence or absence of ICI 182,780 on
COMT expression determined by COMT ELISA. Results are
mean ± SEM of four separate experiments (n=4). Statistical
significance at the level of **p<0.01, as compared to untreated
controls. ## represents significance at level of p<0.01, # p<0.05,
between the two designated treatment groups.
doi: 10.1371/journal.pone.0074065.g003
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p<0.0001, n=30). Such reduction can be effectively blocked by
ER antagonist, ICI 182,780, confirming that reduction of COMT
by 17β-estradiol is mediated by ER (Figure 3E).
Suppression of COMT expression by BPA, BBP and
DBP in COMT ELISA was comparable to western
blotting results
Using aliquots of the same samples after treated with
different concentrations of BPA, BBP, DBP or 17β-estradiol,
the resultant changes in COMT protein levels were determined
in COMT ELISA and SDS-PAGE/Western analysis. Exposure
to BPA (10-9-10-7M) reduced COMT expression in a dose-
dependent manner (Spearman r = 0.83; p<0.0001, n=18) in six
separate estimations in duplicate. Furthermore, BBP (10-7M)
and DBP exposure (10-9-10-7M) significant reduced COMT
expression (all p<0.05), which was significantly attenuated by
ICI 182,780 (all p<0.05) (Figure 3E). The accuracy of the
ELISA was illustrated by the fact that the average coefficient of
variation of the duplicates of the COMT estimates following
BPA treatment over the 6 curves was 7%. This suppressive
effect of all three plasticizers, BPA, BBP and DBP, was
abolished by the presence of ICI 182,780 (Figure 3E). The
estrogenic effect of these plasticizers as expressed by
percentage reduction in COMT expression from ELISA was
similar and comparable to those determined by SDS-PAGE/
Western analysis. For the two methods, the Spearman rank
correlation coefficient is r=0.78 (p<0.0001, n=24).
Discussion
Environmental contaminants with endocrine disrupting
potential pose an increasing threat to public health. Current
methods of assessing such compounds involve a combination
of in vivo and in vitro assays, including the comprehensive
“two-generation” rat test [10]. However, these in vivo tests are
always time-consuming and expensive that it would be virtually
impossible to assess all chemicals in short period of time; even
the “one-generation test” [22] would require a formidable
number of animals and time to complete the required list in the
near future. Alternatively, there are in vitro screening assays for
assessment of estrogenic and hormonal activity [12,13].
However, due to the nature of diverse variety of testing
substances targeting different cellular components, detection
by one single assay would not adequately cover all potential
cellular toxicity pathways. Given the inherited limitations for the
existing in vitro assays [14,15], combination of in vivo and in
vitro assays remains by far the best strategy.
One possible strategy in developing a more representative
screening would be to target the physiological response of
various endogenous protein markers, as a reflection of
downstream convergence from various estrogenic signals. In
this study, we described an in vitro assay to quantify estrogenic
effects based on changes of cellular COMT protein level. This
novel bioassay is based on the physiological response of
MCF-7 cells to suppress S-COMT protein expression under
ER-mediated estrogenic stimulation [8,16]. Both endogenous
estrogen and its catechol metabolites can suppress COMT
expression and activity, and has been suggested to be a risk
factor for estrogen-associated cancers [21]. Moreover, COMT
expression is suppressed by xenoestrogens, including
phthalate-based plasticizers [17,18]. It is not surprising that
absorption of these estrogenic agents may adversely affect
COMT expression and perturb the metabolic processes of
endogenous estrogen. Therefore, this assay not only
determines a direct transcriptional regulatory effect of COMT
via estrogenic activity of a compound, but also implicates
potential adverse effects to estrogen metabolism due to
abnormal suppression of COMT expression.
Human COMT is retrospectively regulated by estrogen
[8,16]. The 5’ flanking region of the COMT gene that gives rise
to the S-COMT transcript contains numerous well-separated
estrogen-response-element (ERE) half-sites, which are
involved in the estrogenic regulation of S-COMT expression [8].
These differ from classical EREs in that the number of bases
between the half-sites is much greater than between half-sites
that form classical EREs. In addition, S-COMT is down-
regulated by estradiol, and so effects on S-COMT via these
sites are likely to involve different mechanisms of interaction of
the ER with DNA and different co-factors than those mediating
gene transcription via classical EREs. Thus, the results may
reflect alternative mechanisms that supplement results of tests
based on the classical ERE to detect potential estrogenic
endocrine disruptors. As shown by our ELISA assay at graded
concentrations of estradiol (Figure 3D), the sensitivity of
response in the form of suppression of COMT protein
expression in MCF-7 cells can be achieved at the lowest
estradiol concentration of picomolar (10-12M) level. This
sensitivity level is comparable with the detection limit as
reported for the traditional estrogenic cell proliferation assay
(i.e. ~30pM) [14]. Although the mammalian cell (e.g. T47D
human breast cancer cells) reporter gene assay offers even
higher assay sensitivity up to femtomolar (10-15M) level, these
assays require utilization of transfected reporter gene construct
engineered with multiple EREs. Due to the amplification of
response signal by the multiple response elements and the
ectopic expression of luciferase, this way of detection greatly
increases the assay sensitivity, but may not satisfactorily reflect
the actual physiological situation. For example, previous
studies have shown that BPA binds with low affinity to the ER
but exerts serious developmental problems in vivo [23].
To demonstrate the efficacy of our assay, we investigated
the estrogenic effects of three plasticizers commonly used in
plastics manufacturing. Chronic exposure of BPA, similar to
other phthalate-based plasticizers, e.g. BBP and DBP, is widely
recognized as environmental pollutant and a major risk factor
to hormone-related carcinogenesis in rodents [24–26]. In this
test system, we have shown that all three tested plasticizers
can significantly reduced S-COMT level via ER-mediated
transcription in a dose-dependent manner, thus illustrating the
possibility that different arrangement of the ER half-sites and
different co-factors may well affect ligand binding to the
receptor and hence the need for a range of simple and
sensitive assays to ensure adequate assessment of estrogenic
potential in an untested compound. The specificity of
estrogenic action was shown by the fact that ER antagonist, ICI
182,780, blocked the action of these plasticizers in suppressing
COMT Expression Quantifies Estrogenic Activity
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COMT protein expression. Since the traditional ER binding and
the transcriptional activation assays have limitations to
differentiate specific pathways affected by the tested
compounds, a combination of a physiologically sensitive
marker (S-COMT expression) and a simple immuno-assay for
the marker (the novel competitive ELISA) makes the system
suitable as a preliminary screen for potential estrogenic agents.
We verified the results of our novel ELISA by showing that
these were highly correlated with those obtained by traditional
Western blotting. The applicability of this assay is further
supported by our previous studies that a variety of phthalate-
based plasticizers, e.g. DEHP, DINP [17], and polychlorinated
biphenyls [18] can modulate S-COMT expression in MCF-7
cells. Therefore, the relative changes in COMT expression after
exposure to potential estrogenic compounds may be correlated
to the disruption, which may potentially occur to estrogen
metabolism via ER-mediated COMT suppression.
In conclusion, our study demonstrates a quick assay of
estrogenic effects in a cell-based ELISA, as validated by
suppression of COMT expression by three estrogenic
plasticizers, BPA, BBP, and DBP. In response to the increasing
demand in screening methods for endocrine disrupting
potential, assessment of cellular response of COMT expression
to estrogenic agents serves to screen hazardous chemicals in
a fast and economical manner, complementing current in vitro
and in vivo tests for estrogenic activity.
Materials and Methods
Materials
All test reagents and chemicals including the tested
plasticizers (i.e. bisphenol-A (BPA), benzyl butyl phthalate
(BBP), and Di-n-butyl phthalate (DBP)), dithiothreitol (DTT),
17β-estradiol (E2), and phenylmethylsulfonyl fluoride were
purchased from Sigma-Aldrich Chemical Company,
(Milwaukee, WI, USA). Human breast adenocarcinoma MCF-7
cell line (human breast adenocarcinoma; HTB-22), human
embryonic kidney HEK293 cell line (CRL-1573), and human
neuroblastoma SH-SY5Y cells (CRL-2266; ATCC) were
obtained from the American Type Culture Collection (ATCC;
Rockville, MD). Charcoal-stripped bovine calf serum, RPMI
without phenol red indicator, penicillin-streptomycin, insulin and
10% sodium dodecyl sulfate (SDS) stock solution were
purchased from GIBCO/BRL (Grand Island, NY, USA).
Prestained protein molecular weight standard markers were
from Fermentas Int. Inc. (Ontario, Canada). Horseradish
peroxidase (HRP)-conjugated anti-sheep immunoglobulin
antiserum was obtained from DAKO (Glostrup, Denmark).
ECL-plus western blotting detection reagents were purchased
from Amersham Pharmacia Biotech (NJ, USA). The estrogen
receptor antagonist (ICI 182,780) was purchased from Tocris
(Ellisville, MO, USA). Sheep polyclonal anti-human COMT
antibody was raised by The Binding Site Ltd. (Birmingham,
UK), and affinity purified as previously described [14]. This
antibody is directed against a linear epitope of human COMT
peptide which is present in both membrane bound (MB)- and
soluble (S)- forms of COMT. The mouse monoclonal anti-
human actin (C-2) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Cell culture and treatments
Human MCF-7 cells were chosen as a cell model for
assessment of estrogenic effects because these cells are
responsive to estrogen via classical estrogen receptor (ER)-
mediated pathway [17]. The estrogen-responsive S-COMT
isoform is dominantly expressed in MCF-7 cells [14]. MCF-7
cells in RPMI containing 10% heat-inactivated fetal bovine
serum, antibiotics (100U/ml of penicillin and 100µg/ml of
streptomycin), and 1µg/ml insulin in humidified 5% CO2 at
37°C. Cells (105) were seeded onto 24-well plate and incubated
in fresh RPMI. Both 17β-estradiol (a potent S-COMT
suppressor) was dissolved at stock concentration of 1mM in
PBS. The three testing compounds, BPA, BBP and DBP were
freshly prepared at stock concentration of 10mM in DMSO.
After the cells had reached 70% confluence, the medium was
replaced with phenol red-free RPMI supplemented with 10%
charcoal-stripped calf serum depleted of exogenous estrogen,
antibiotics and insulin, for 48 hours. After the pre-incubation,
cells were exposed to either a fixed concentration of E2 (10-6M;
positive control) or graded concentrations of BPA (10-5, 10-7,
and 10-9M), BBP (10-7 and 10-9M), or DBP (10-7 and 10-9M), with
or without the anti-estrogen, ICI 182,780 (10-7M). Cells were
harvested after an additional 48 hours of incubation for
determination of COMT expression level by ELISA, and SDS-
PAGE/Western analysis as described below. Experiments were
repeated a minimum of three times.
Development of competitive ELISA for COMT
Human COMT is expressed in two forms originating from
transcripts of the same gene, which has two transcription
initiation sites – S-COMT in cytosol and membrane-bound
COMT (MB-COMT). The development of a typical competitive
ELISA requires sources of COMT for the standard control
protein to generate the standard curve, and a tagged COMT to
act as a detectable competitor against either the standard
controls or endogenous COMT in samples. Both S-COMT and
MB-COMT can be captured by anti-COMT detection antibody
in the ELISA. For simplicity of cloning, only the full-length MB-
COMT was chosen as the basis of the detectable competitor,
which was tagged with a novel epitope – termed “NE” (patent
application -US 20100081147; EP 2328909; CN 102203119),
whereas the standard control MB-COMT protein was tagged
with FLAGTM to aid detection in the purification steps following
synthesis. These two recombinant proteins compete with each
other at different ratio for the binding to anti-COMT detection
antibody in the ELISA to generate the standard curve. An
antibody against the NE tag was required as part of the
detection step in the ELISA.
Molecular cloning of recombinant MB-COMT-NE protein
A full length human MB-COMT cDNA was generated from
total RNA isolated from human neuroblastoma SH-SY5Y cells
(CRL-2266; ATCC) by one-step RT-PCR (Titan One Tube RT-
PCR Kit, Roche) according to the manufacturer’s protocol,
using a pair of primer specifically designed for addition of NE
COMT Expression Quantifies Estrogenic Activity
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cDNA fragment at 3’-end of MB-COMT. To generate BamHI-
COMT-NE-EcoRI cDNA fragment for directional cloning into
the expression plasmid (pcDNA3.1(+); Invitrogen or pGEX-6p1;
GE Healthcare), restricted enzyme sites (BamHI and EcoRI)
were inserted by a second PCR using forward primer for MB-
COMT (5’-
CGCGGATCCGCCACCATGCCGGAGGCCCCGCCTCTGC-3’




GCCTGGGC-3’). The MB-COMT DNA insert (BamHI-COMT-
NE-EcoRI) and empty vector (pcDNA3.1(+) or pGEX-6p1) were
digested separately by restriction enzymes (BamHI and
EcoRI), and ligated to the pcDNA3.1(+) or pGEX-6p1 vector at
4oC overnight. A similar strategy was used to generate MB-
COMT-Flag, where the NE sequence was replaced with the
FLAG sequence.
Expression of recombinant MB-COMT-NE and MB-
COMT-FLAG proteins
For expression of either recombinant MB-COMT-NE or MB-
COMT-FLAG protein in E. Coli (BL21), a positive clone was
culture in LB broth supplemented with ampicillin (50g/ml) and
incubated at 37°C with vigorous shaking until the optical
density reading of the bacterial culture reached ~0.6 (at λ =
600nm). The culture was induced with isopropylthio-β-D-
galactoside (0.1mM) and cultured for another 4 hours. Cells
were collected by centrifugation and were sonicated in ice-cold
lysis buffer (50mM Tris-Cl, pH 7.5, 200mM NaCl),
supplemented with 5mM 1,4-dithiothreitol (DTT) and 1mM
PMSF. The expressed recombinant MB-COMT-NE or MB-
COMT-FLAG protein from the bacterial lysate was purified by
passing through a commercially available glutathione-S-
transferase (GST)-purification column (GSTrap™ FF, GE
Healthcare). The target protein band was visualized by SDS-
PAGE after Coomassie blue staining of the gel, and
characterized by Western blotting.
Construction of COMT competitive ELISA
Ninety-six-well plates were pre-coated with varying amounts
of a polyclonal COMT antibody directed against a common
epitope in S- and MB-COMT (capture antibody) at 4°C
overnight. A series of diluted MB-COMT-NE standards were
added to the wells and incubated at 37°C for 2 hours to
determine the optimum amount of capture antibody required.
After subsequent washes with TBS-Tween, rabbit anti-NE
antibody (detection antibody) and HRP-conjugated anti-rabbit
antibody were sequentially dispensed to assay wells and
incubated at room temperature for 1 hour. After washes, TMB
substrate was added and incubated in the dark for 30 min for
colorimetric development. The optical density (OD) of each well
at 450nm was measured using a microplate reader
immediately after addition of sulphuric acid (0.1M, 1: 1 v/v).
The optimum amount of capture antibody was 0.1µg per well.
Once this was established, a series of standard curves was
developed to ascertain the optimum amount of MB-COMT-NE.
Once the optimum coating with capture antibody and amount of
competitor MB-COMT-NE were determined, a series of
standard curves was developed using a range of MB-COMT-
FLAG concentrations (0-80µg) to ascertain the sensitivity and
reproducibility of the assay.
Western blotting
Changes of S-COMT expression in MCF-7 cells were
determined by SDS-PAGE/western blotting following our
previously described protocol [17] to compare the results with
those obtained by our COMT ELISA. Briefly, cells were washed
with ice-cooled PBS and harvested in buffer containing: 50mM
Tris-Cl, pH 7.4, 150mM NaCl, 1% sodium deoxycholate, 1mM
EDTA, 1% Triton X-100, 0.1% SDS, 1mM phenylmethylsulfonyl
fluoride, supplemented with protease inhibitor cocktail at 4°C.
Lysates were clarified by centrifugation at 4°C for 15 min. at
12,000 r.p.m. Sample protein concentrations were determined
by Bradford assay. Equal amounts of protein were boiled for 10
min at 95oC in sample buffer containing: 62.5mM Tris, pH 6.8,
100mM DTT, 2% SDS, 10% glycerol, and 0.002%
bromophenol blue. Samples (20µg per lane) were
electrophoresed on 12% SDS-polyacrylamide gels and then
transferred onto nitrocellulose membrane. Resulting blot were
blocked with 5% non-fat skimmed milk in TBS and probed with
antibodies directly against COMT (1:1000) or β-actin (1:1000).
For chemiluminescence detection, blots were incubated with
HRP-conjugated secondary antibodies (1:5000) followed by
ECL-plus substrate detection. Immunoblots were quantified by
computerized scanning densitometry.
Effect of 17β-estradiol and BPA on S-COMT expression
in competitive ELISA
MCF-7 cell lysates were prepared from cells treated either
with graded doses of E2, BPA, BBP or DBP as indicated above
and normalized to the same concentration with ice-cooled PBS
supplemented with protease inhibitor cocktail (Roche). Equal
amounts of lysate (50µg) were mixed with 2µg of recombinant
MB-COMT-NE and topped up to 100µl with BSA-containing
sample diluent. A serial dilution of standards each containing
recombinant MB-COMT-NE (2µg) and MB-COMT-FLAG
(0-80µg) in 100µl sample diluent were prepared. Duplicate
aliquots (100µl) of either standards or cell lysate preparations
were added to wells and the ELISA performed as above.
Statistical analysis
Statistical analyses were carried out using the Prism
(GraphPad Software Inc.). Data are expressed as mean ±
standard error mean (S.E.M.) from at least three independent
experiments. Statistical significance among individual groups
was calculated by the one-way ANOVA followed by Tukey’s
post-hoc multiple comparison, and independent t-test.
Spearman correlation coefficients (r) between various
parameters were calculated, because normal distributions
could not be assumed. Differences and r values were
considered significant at a level of p<0.05.
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